Does undetectable basal Tg measured with a highly sensitive assay in the absence of antibodies and combined with normal ultrasonography ensure the absence of disease in patients treated for thyroid carcinoma?;Tireoglobulina basal indetectável medida com ensaio ultrassensível na ausência de anticorpos e combinada com ultrassonografia normal assegura ausência de doença em pacientes tratados de câncer de tireoide?

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 56, Issue 2, 2012, Pages 149-151

  Rosário, Pedro Weslley ^a   Filho, Augusto Flávio Campos Mineiro ^a  

^a Núcleo de Pós Graduação e Pesquisa da Santa Casa de Belo Horizonte   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861311416     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302012000200009     Document Type: Article

References (10)

1. Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays? Clin Endocrinol. 2008;68:338-342.
2. Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol. 2007;67:434-441.
3. Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F, Spriano G. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant thyrotropin stimulated assay and inaging procedures. Clin Chem Lab Med. 2006;44:648-652.
4. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, et al. The use of ultrasensitive thyroglobulin assays reduces but not abolishes the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest. 2011;34(8):e219-e223. Epub 2011 Mar 7.
5. Smallridge RC, Meek S, Morgan MA, Gates GS, Fox TP, Grebe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab. 2007;92:82-87.
6. Giovanella L, Maffioli M, Ceriani L, De Palma D, Spriano G. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. Clin Chem Lab Med. 2009;47:1001-1004.
7. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab. 2011;96:1352-1359.
8. Zöphel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid. 2003;13:861-865.
9. Rosario PW. Câncer de tireóide: seguimento com radioiodo. In: Volpi E, Friguglietti C, Kulcsar MA. Câncer da tireóide. Abordagem multidisciplinar. 1th ed. São Paulo: AC Farmacêutica; 2010. p. 280-283.
10. Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53:884-887.